Key Documents

View All Documentation

C2285000

Clobetasone butyrate

Name: Clobetasone butyrate
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

21-Chloro-9-fluoro-17-hydroxy-16-methylpregna-1,4-diene-3,11,20-trione 17-butyrate

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):

C₂₆H₃₂ClFO₅

CAS Number:

25122-57-0

Molecular Weight:

478.98

NACRES:

NA.24

PubChem Substance ID:

329774989

UNSPSC Code:

41116107

MDL number:

MFCD00133196

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Properties

grade

pharmaceutical primary standard

API family

clobetasone

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

CCCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)C(=O)C[C@]12C)C(=O)CCl

InChI

1S/C26H32ClFO5/c1-5-6-22(32)33-26(21(31)14-27)15(2)11-19-18-8-7-16-12-17(29)9-10-23(16,3)25(18,28)20(30)13-24(19,26)4/h9-10,12,15,18-19H,5-8,11,13-14H2,1-4H3/t15-,18-,19-,23-,24-,25-,26-/m0/s1

InChI key

FBRAWBYQGRLCEK-AVVSTMBFSA-N

Description

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Clobetasone butyrate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Still not finding the right product?

Explore all of our products under Clobetasone butyrate

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

涉药品监管产品

This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Highly potent and moderately potent topical steroids are effective in treating phimosis: a prospective randomized study.

Stephen Shei Dei Yang et al.

The Journal of urology, 173(4), 1361-1363 (2005-03-11)

We report a prospective randomized study comparing the effects of highly potent and moderately potent topical steroids in treating pediatric phimosis. A total of 70 boys 1 to 12 years old with phimosis were randomly assigned to receive topical application

Acute anterior uveitis.

Andreé Curi et al.

Clinical evidence, (9)(9), 691-696 (2004-09-16)

Tacrolimus ointment vs steroid ointment for eyelid dermatitis in patients with atopic keratoconjunctivitis.

E Nivenius et al.

Eye (London, England), 21(7), 968-975 (2006-05-09)

The main objective of this explorative study was to evaluate if tacrolimus ointment could be safer than corticosteroid ointment, with special reference to the intraocular pressure in the treatment of eyelid eczema in patients with atopic keratoconjunctivitis (AKC). Secondary aims

View All Related Papers

Global Trade Item Number

SKU	GTIN
C2285000	04061833792513